Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MIST with free AI briefings, catalyst countdowns, and dilution alerts.

MIST · Milestone Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$145.4M Cash on Hand
18.2mo Cash Runway
16.1% Short Interest
$3.86 Analyst Target (7)
Follow MIST by email Get an email when MIST reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MIST, unsubscribe in one click. Privacy

📣 What MIST Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Etripamil
FDA approved Dec 2025 · Cardamyst
Atrial Fibrillation Phase 3 · NCT06716021 Recruiting
Etripamil NS 70 mg Paroxysmal Supraventricular Tachycardia Phase 3 · NCT04072835 Completed
Etripamil Test Dose Paroxysmal Supraventricular Tachycardia Phase 3 · NCT03464019 Terminated
Etripamil Nasal Spray 70mg Healthy Chinese Subjects Phase 1 · NCT05511870 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MIST holds $145.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $24M/quarter from operations, an estimated runway of 18.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 47 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MIST files for a raise →

👥 Who Owns MIST

Insiders 0.9% Institutions (87 holders) 52.8% Public and other holders 46.3%
HolderTypeShares% of sharesAs of
RTW Investments, LP Institution (13G, 5%+) 12,356,953 9.93% 2026-03-31
Pavaki Capital Management LLC Institution (13G, 5%+) 9,067,848 7.28% 2025-12-31
Propel Bio Management, LLC Institution (13G, 5%+) 8,861,186 7.12% 2025-07-11
Adage Capital Management, L.P. Institution (13G, 5%+) 8,000,000 6.43% 2026-03-31
Point72 Asset Management, L.P. Institution (13F) 5,467,247 4.39% 2026-09-30
Simplify Asset Management, Inc. Institution (13F) 3,349,379 2.69% 2026-09-30
Two Sigma Investments, LP Institution (13F) 1,721,021 1.38% 2026-09-30
Kalehua Capital Management LLC Institution (13F) 1,651,258 1.33% 2026-09-30
RVW Wealth, LLC Institution (13F) 1,148,260 0.92% 2026-09-30
Marshall Wace LLP Institution (13F) 1,117,642 0.90% 2026-09-30
Joseph Oliveto
President and CEO, Director · +2.36M options
Insider 446,244 0.36% 2026-04-16
Lorenz Muller
Chief Commercial Officer · +770,966 options
Insider 205,406 0.16% 2025-12-12

Share count 124,498,693 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-06-10
filed 2026-06-12
Wills Robert James
Option award (A) 77,000 – –
2026-06-10
filed 2026-06-12
Saik Andrew
Option award (A) 77,000 – –
2026-06-10
filed 2026-06-12
Fischer Seth H. Z.
Option award (A) 77,000 – –
2026-06-10
filed 2026-06-12
TOMSICEK MICHAEL JOHN
Option award (A) 77,000 – –
2026-06-10
filed 2026-06-12
Giles Lisa M.
Option award (A) 77,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-12-13 CARDAMYST™ (etripamil) NDA +24.9% -2.7% -10.8%

Browse all historical PDUFA outcomes →

Get the full MIST picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MIST and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.